Theravance Biopharma, Inc.

Over the last 90 days, Theravance Biopharma (TBPH) reported zero cyber incidents and zero red-flag 8-K filings—no bankruptcies, restatements, or officer departures detected in our pipeline. The absence of near-term signals is worth noting, though a 90-day window captures only recent activity; deeper risk often emerges across longer timelines. The full $49 Report extends coverage to twelve months of SEC filings, calculates dilution risk scores from equity issuances, maps financing history and runway, and surfaces AI-detected risk signals that static disclosures may not highlight. Understanding whether TBPH's quiet period masks structural pressures requires that fuller context.